N-[(1,1-二甲基乙氧基)羰基]-3-氟-苯丙氨酸 | 87184-23-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-[(1,1-二甲基乙氧基)羰基]-3-氟-苯丙氨酸
• 中文别名: N-BOC-DL-3-氟苯丙氨酸
• 英文名称: Boc-DL-m-FPhe
• 英文别名: N-Boc-DL-3-fluorophenylalanine；Boc-3-fluorophenylalanine；L-2-tert-butoxycarbonylamino-3-(3-fluoro-phenyl)-propionic acid；2-[(Tert-butoxycarbonyl)amino]-3-(3-fluorophenyl)propanoic acid；3-(3-fluorophenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid
• CAS: 87184-23-4
• 化学式: C₁₄H₁₈FNO₄
• 分子量: 283.3
• InChiKey: FPCCREICRYPTTL-UHFFFAOYSA-N

物化性质

• 沸点：
  425.0±40.0 °C(Predicted)
• 密度：
  1.216±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-[(1,1-二甲基乙氧基)羰基]-3-氟-苯丙氨酸 在 碳酸氢钠 、 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 反应 2.0h， 生成 Boc-DL-m-FPhe-L-Met-L-Met
  参考文献：
  名称：

  Transport of antimicrobial agents using peptide carrier systems: anticandidal activity of m-fluorophenylalanine-peptide conjugates

  摘要：

  A series of di- and tripeptides containing D- and L-m-fluorophenylalanine was prepared and tested in vitro for the ability to inhibit the growth of the yeast Candida albicans. The results demonstrate that peptides containing L-m-fluorophenylalanine inhibited the growth of C. albicans with minimum inhibitory concentrations (MIC's) ranging from 0.5 to 63 micrograms/mL. The parent L-m-fluorophenylalanine and peptides containing D-m-fluorophenylalanine were inactive (MIC greater than 250 micrograms/mL) in these tests. The results of competitive antagonism studies support peptide transport mediated entry of the inhibitory peptides, followed by release of L-m-fluorophenylalanine inside the cell.

  DOI：

  10.1021/jm00366a013
• 作为产物：
  描述：

  2-(叔丁氧羰基氧亚氨基)-2-苯乙腈 、 3-氟-DL-苯丙氨酸 在 三乙胺 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 2.5h， 以68%的产率得到N-[(1,1-二甲基乙氧基)羰基]-3-氟-苯丙氨酸
  参考文献：
  名称：

  Transport of antimicrobial agents using peptide carrier systems: anticandidal activity of m-fluorophenylalanine-peptide conjugates

  摘要：

  A series of di- and tripeptides containing D- and L-m-fluorophenylalanine was prepared and tested in vitro for the ability to inhibit the growth of the yeast Candida albicans. The results demonstrate that peptides containing L-m-fluorophenylalanine inhibited the growth of C. albicans with minimum inhibitory concentrations (MIC's) ranging from 0.5 to 63 micrograms/mL. The parent L-m-fluorophenylalanine and peptides containing D-m-fluorophenylalanine were inactive (MIC greater than 250 micrograms/mL) in these tests. The results of competitive antagonism studies support peptide transport mediated entry of the inhibitory peptides, followed by release of L-m-fluorophenylalanine inside the cell.

  DOI：

  10.1021/jm00366a013

文献信息

• [EN] PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS<br/>[FR] DÉRIVÉS DE LA PYRIDAZINE INHIBITEURS DU FACTEUR XIA
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2009114677A1

  公开（公告）日：2009-09-17

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein the variables A, L1, L2, R2, R11, and M are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

  本发明提供了式（I）的化合物：或其立体异构体、互变异构体或药学上可接受的盐，其中变量A、L1、L2、R2、R11和M如本文所定义。这些化合物是选择性因子XIa抑制剂或fXIa和血浆激肽原的双重抑制剂。本发明还涉及包含这些化合物的药物组合物以及使用它们治疗血栓栓塞和/或炎症性疾病的方法。
• Substituted hydantoins
  申请人：Goodnow, Alan Robert

  公开号：US20060063814A1

  公开（公告）日：2006-03-23

  The present invention relates to compounds of the formula which are useful in treating diseases characterized by the hyperactivity of MEK. Accordingly the compounds are useful in the treatment of diseases, such as, cancer, cognative and CNS disorders and inflammatory/autoimmune diseases.

  本发明涉及以下公式的化合物，这些化合物在治疗以MEK高活性为特征的疾病方面具有用途。因此，这些化合物在治疗癌症、认知和中枢神经系统疾病以及炎症/自身免疫疾病等疾病方面具有用途。
• METHOD FOR INHIBITING PROLIFERATION OF TUMOR CELLS
  申请人：Niu Huifeng

  公开号：US20080207563A1

  公开（公告）日：2008-08-28

  Disclosed are methods for synergistically inhibiting the proliferation of tumor cells by contacting the tumor cells with a MEK inhibitor compound and erlotinib, either sequentially or simultaneously. Also disclosed are methods for inhibiting the proliferation of tumor cells in a human, by administering to the human, sequentially or simultaneously, an amount of erlotinib and a MEK inhibitor compound, wherein the amounts are effective, in combination, to synergistically inhibit the proliferation of the tumor cells in the human.

  本文揭示了通过将肿瘤细胞与MEK抑制剂化合物和厄洛替尼接触，无论是顺序地还是同时地，协同抑制肿瘤细胞增殖的方法。还揭示了通过向人体逐步或同时施用厄洛替尼和MEK抑制剂化合物的方法，其中这些量在组合时对于协同抑制人体内肿瘤细胞增殖是有效的。
• Synthesis and antimycobacterial activity of prodrugs of indeno[2,1-c]quinoline derivatives
  作者：Ram Shankar Upadhayaya、Popat D. Shinde、Sandip A. Kadam、Amit N. Bawane、Aftab Y. Sayyed、Ramakant A. Kardile、Pallavi N. Gitay、Santosh V. Lahore、Shailesh S. Dixit、András Földesi、Jyoti Chattopadhyaya

  DOI：10.1016/j.ejmech.2011.01.053

  日期：2011.4

  we have reported anti-TB properties of a new class of conformationally-constrained indeno[2,1-c]quinolines, which are although considerably active (MIC 0.39–0.78 μg/mL) suffered from intense solubility problems. We thought of improving their bioavailability by prodrugs approach. Accordingly esters of the “Lead” indeno[2,1-c]quinolines 1, 15 and 27 derivatives were synthesized and their prodrug nature

  最近，我们报道了一类新的构象受限的茚并[ 2,1 - c ]喹啉类药物的抗结核特性，尽管它们的活性相当大（MIC 0.39–0.78μg/ mL），但存在严重的溶解性问题。我们考虑通过前药方法提高其生物利用度。“先驱”茚并因此酯[2,1- c ^ ]喹啉1，15周27的衍生物的合成和在生理pH下它们的前体药物的性质得到了证实。评价前药对结核分枝杆菌的抗分枝杆菌活性通过MABA测定的H37Rv表明，与它们各自的母体化合物相比，它们的抗结核病活性提高了2至4倍，水溶性增加，选择性指数更高。这些前药的MIC在<0.20–6.0μg/ mL的范围内，通常在VERO细胞中未观察到细胞毒性。
• HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
  申请人：Agouron Pharmaceuticals, Inc.

  公开号：US20040204591A1

  公开（公告）日：2004-10-14

  The present invention concerns processes for preparing compounds of formula (I-H), or a prodrug, pharmaceutically active metabolite, or pharmaceutically active salt or solvate thereof, 1 which are useful as inhibitors of the HIV protease enzyme.

  本发明涉及制备式(I-H)化合物的过程，或其前药、药理活性代谢物、药理活性盐或溶剂化合物的过程，这些化合物可用作HIV蛋白酶酶抑制剂。